Veru Inc. filings document regulatory disclosures for a Wisconsin biopharmaceutical company whose common stock trades on the Nasdaq Capital Market under VERU. Recent 8-K reports cover financial results, clinical program updates, material agreements, settlement of promissory-note obligations, security-holder rights, and capital-structure actions, including the completed 1-for-10 reverse stock split.
Proxy and annual-meeting records describe board elections, auditor ratification, executive compensation votes, and amendments to the 2018 Equity Incentive Plan. The filing record also includes Nasdaq listing-compliance disclosures and exhibits tied to Veru’s enobosarm and sabizabulin development programs.
VERU INC. Chief Admin Officer and CFO Michele Greco received a grant of options to purchase 164,000 shares of common stock at an exercise price of $2.25 per share. These are compensation-related awards, not open-market share purchases or sales.
According to the vesting schedule, options for one-third of the shares vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, and the options expire on May 4, 2036. After this grant, Greco holds 164,000 options directly.
VERU INC. director Loren Mark Katzovitz received a grant of stock options covering 102,000 shares of common stock. The options have an exercise price of $2.25 per share and expire on May 4, 2036. One-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029.
VERU INC. director Hyun Grace received a grant of options to buy 97,000 shares of common stock at an exercise price of $2.25 per share. These are compensation-related options, not an open-market purchase, and give her the right to buy shares in the future.
According to the vesting schedule, options for one-third of the shares vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, with all unexercised options expiring on May 4, 2036. After this grant, she holds options for 97,000 shares directly.
VERU INC. director Michael L. Rankowitz received a grant of options on 100,000 shares of Veru common stock. The options have an exercise price of $2.25 per share and expire on May 4, 2036. One-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029.
VERU INC. director Lucy Lu reported receiving a grant of 104,000 common stock options as compensation. The options have an exercise price of $2.25 per share and expire on May 4, 2036. One-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, and Lu holds 104,000 options following this grant.
VERU INC. disclosed that Chief Scientific Officer K. Gary Barnette received a compensation-related grant of stock options. The award covers 160,000 options to acquire Veru common shares at an exercise price of $2.25 per share, with all options held directly after the grant.
According to the vesting terms, options for one-third of the shares vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, and the options expire on May 4, 2036. This filing reflects an equity incentive grant rather than an open-market purchase or sale.
VERU INC. Chief Corporate Officer Harry Fisch received a grant of stock options covering 160,000 shares of common stock. The options have an exercise price of $2.25 per share and expire on May 4, 2036.
According to the vesting schedule, one-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029. Following this grant, Fisch holds 160,000 options to acquire VERU common shares directly, reflecting a compensation-related equity award rather than an open-market purchase.
Veru Inc. registers up to $200,000,000 of common stock, debt securities, preferred stock, warrants, purchase contracts, rights and units from time to time under a shelf registration.
This prospectus provides a general description of the securities and states that specific terms, offering price and net proceeds will be set forth in a prospectus supplement. The offering is subject to completion and effectiveness and may be sold directly, through agents, dealers, or underwriters.